Ocular Safety Profile of BRAF and MEK Inhibitors

医学 药物警戒 优势比 不利影响 MEK抑制剂 置信区间 内科学 回顾性队列研究 葡萄膜炎 肿瘤科 皮肤病科 眼科 MAPK/ERK通路 生物 细胞生物学 激酶
作者
C. Mettler,Dominique Monnet,N. Kramkimel,Jean‐Marc Tréluyer,Luc Mouthon,Antoine P. Brézin,N. Dupin,Marie‐Blanche Valnet‐Rabier,Laurent Chouchana,Benjamin Terrier
出处
期刊:Ophthalmology [Elsevier BV]
卷期号:128 (12): 1748-1755 被引量:25
标识
DOI:10.1016/j.ophtha.2021.05.008
摘要

BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) significantly improved metastatic melanoma prognosis. Ocular adverse effects (OAEs) represent an uncommon but disabling toxicity of these drugs. We aimed to characterize the ocular safety profile of BRAFi or MEKi and to detect possible safety signals.We performed a retrospective, observational, pharmacovigilance study using VigiBase, the World Health Organization global safety database. Ocular adverse effects were classified according to the eye segments and the inflammatory pattern based on the Standardization of Uveitis Nomenclature. Associations among BRAFi monotherapy, MEKi monotherapy, and BRAFi+MEKi combination therapy and OAE reporting were assessed using disproportionality analysis. Results were expressed with the reporting odds ratio (ROR) and its 95% confidence interval (CI).From January 2010 to October 2019, 1568 OAE cases were reported with BRAFi or MEKi. Among them, 1006 cases with sufficient data were included, corresponding to 310 (30.8%), 124 (12.3%), and 572 (56.9%) cases reported with BRAFi, MEKi, or BRAFi+MEKi combination therapy, respectively. BRAF inhibitor monotherapy was significantly associated with the reporting of iris and ciliary body abnormalities (ROR, 8.7; 95% CI, 6.0-12.5), diffuse abnormalities (ROR, 7.1; 95% CI, 5.4-9.4), anterior uveitis (ROR, 8.6; 95% CI, 6.0-12.1), and panuveitis (ROR, 7.1; 95% CI, 5.4-9.4). MEK inhibitor monotherapy was associated with the reporting of retinal and choroid abnormalities (ROR, 9.5; 95% CI, 7.4-12.2), diffuse abnormalities (ROR, 2.5; 95% CI, 1.1-6.1), and panuveitis (ROR, 2.5; 95% CI, 1.1-6.1). Combinations of BRAFi and MEKi therapies were associated with OAEs from both drugs, with a possible synergistic or additive effect for diffuse abnormalities and panuveitis.Our study characterizes the ocular safety profile of BRAFi and MEKi. We identify possible safety signals for several OAEs not previously reported with BRAFi and MEKi. Our data provide the rationale for a personalized management of OAE in patients with BRAFi+MEKi combination therapy according to the type of ocular reaction.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
852应助jingwenli21采纳,获得10
刚刚
刚刚
踏实映天发布了新的文献求助10
刚刚
英俊的铭应助酷炫翠桃采纳,获得10
1秒前
辛辛发布了新的文献求助10
1秒前
月明完成签到,获得积分20
1秒前
1秒前
皮蛋_WH完成签到,获得积分10
1秒前
SYLH应助JingP采纳,获得20
2秒前
瘦瘦妖妖发布了新的文献求助10
2秒前
3秒前
3秒前
端庄的煎蛋完成签到,获得积分0
3秒前
4秒前
枳酒发布了新的文献求助30
5秒前
5秒前
6秒前
6秒前
6秒前
乐乐应助xueer采纳,获得30
6秒前
寸愿完成签到,获得积分10
6秒前
Hello应助月明采纳,获得10
6秒前
7秒前
田田完成签到,获得积分10
8秒前
论太刀虾发布了新的文献求助20
9秒前
11秒前
梦XING发布了新的文献求助10
11秒前
11秒前
11秒前
houfei完成签到,获得积分10
11秒前
happpy发布了新的文献求助10
11秒前
long0809发布了新的文献求助10
11秒前
贪玩的台灯完成签到,获得积分20
11秒前
11秒前
斯文败类应助枳酒采纳,获得30
12秒前
13秒前
时柚发布了新的文献求助10
13秒前
坦率的傲芙完成签到,获得积分10
13秒前
JamesPei应助酷酷念瑶采纳,获得10
13秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974797
求助须知:如何正确求助?哪些是违规求助? 3519250
关于积分的说明 11197623
捐赠科研通 3255405
什么是DOI,文献DOI怎么找? 1797769
邀请新用户注册赠送积分活动 877156
科研通“疑难数据库(出版商)”最低求助积分说明 806202